Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

CDD-0102

Our opinion on this compoundSingle-lab provenance

46/100

Selective M1 partial agonist with clean preclinical tolerability story and IND filing but no published clinical read-out

Look, CDD-0102 sits at a genuinely interesting position in the muscarinic pharmacology space: it’s a well-engineered research tool targeting one of the most validated pathways in cognitive neuroscience, and it improves meaningfully on the compounds that came before it. The cholinergic hypothesis of Alzheimer’s disease has driven M1 agonist research since the 1980s, and the first generation of M1-preferring compounds all failed at the tolerability wall. Xanomeline, sabcomeline, talsaclidine, cevimeline — each produced salivation, GI disturbance, or diaphoresis that made clinical development unsustainable, because none of them cleanly avoided M2 and M3 receptor activity in the periphery. CDD-0102 was engineered specifically to clear that bar, and the preclinical data from the Messer group at Toledo says it mostly does.

The functional selectivity story is real. Binding and functional assay data show meaningful M1/M2 separation, minimal M3 activity at behaviorally relevant doses, and a salivation ED50 around 2.0 mg/kg IP versus cognitive effects beginning at 0.03 mg/kg. Thats roughly a ten-fold therapeutic index on that measure, which is a genuine structural advance over first-generation compounds. The APP processing angle adds something: CDD-0102 stimulates sAPPalpha secretion from M1-expressing CHO cells, consistent with non-amyloidogenic APP processing through alpha-secretase activation. Whether that in vitro signal matters in a human nervous system is the open question, but as a mechanistic probe it’s worth having.

The ASD extension is the most interesting recent development. BTBR mouse data showing attenuation of stereotyped behaviors and glutamate modulation in dorsolateral striatum opens a second research program that’s mechanistically plausible and currently underexplored. The connection between M1 receptor activity and glutamate efflux in corticostriatal circuits is a real phenomenon, and CDD-0102 is one of the cleaner tools available for investigating it in vivo.

Here’s the thing about the evidence base: it’s almost entirely single-source. The behavioral pharmacology, mechanism work, and IND-enabling studies all flow through the Messer lab and its close collaborators. The NCATS BrIDGs program gave the compound federal validation and funded the Phase 1 work, and an IND was filed and Phase 1 initiated, which is meaningful. But no Phase 1 data has entered the peer-reviewed literature as of this writing. The translational signal is essentially zero from an external-replication standpoint, and the AD muscarinic agonist field has decades of cautionary precedent behind it. The xanomeline-trospium approval in schizophrenia (Cobenfy, 2023) has renewed interest in the M1 space, which cuts both ways for CDD-0102: it validates the mechanism broadly, but it also raises the competitive bar.

We think CDD-0102 scores well as a research probe for labs specifically working M1 muscarinic pharmacology or the cholinergic-glutamate axis in ASD models. Theres no clearly better publicly available selective M1 partial agonist with this tolerability profile. But the single-lab origin, the absent clinical read-out, and a field that’s mature even if it isn’t settled keep the overall moderate at 46.

Novelty

45

Mechanism promise

60

In-category differentiation

52

Evidence quality

32

Translational signal

28

Research bench value

55

Rationale CDD-0102 is a credibly engineered M1 muscarinic partial agonist that solves a real tolerability problem its predecessors couldn’t, supported by NCATS BrIDGs funding and an IND filing; however, the evidence base is almost entirely single-source (Messer lab, University of Toledo), no peer-reviewed Phase 1 data has emerged, and the M1 muscarinic agonist space is four decades deep, capping novelty and translational scores hard.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective M1 muscarinic acetylcholine receptor partial agonist of the tetrahydropyrimidine-oxadiazole structural class

A functionally selective partial agonist at the M1 muscarinic acetylcholine receptor developed at the University of Toledo as a cognitive enhancer and neuroprotective agent for Alzheimer’s disease, distinguished from earlier muscarinic agonists by subtype selectivity, low cholinergic adverse-event burden, and oral bioavailability.

Abstract

CDD-0102, the hydrochloride salt of 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (designated CDD-0102A in its salt form), is a functionally selective partial agonist at the M1 subtype of the muscarinic acetylcholine receptor developed at the University of Toledo College of Pharmacy under the direction of W.S. Messer Jr. as a candidate therapeutic for Alzheimer’s disease and related cognitive disorders. The compound occupies the orthosteric acetylcholine-binding site of the M1 receptor with partial agonist intrinsic activity sufficient to activate phospholipase C-coupled signaling, stimulate non-amyloidogenic processing of amyloid precursor protein (APP) through alpha-secretase, and enhance cognitive function in rodent models of cholinergic deficit, while exhibiting minimal functional activity at M2, M4, and M5 muscarinic subtypes and only weak activity at M3 receptors. This functional selectivity profile distinguishes CDD-0102 from the first-generation M1-preferring muscarinic agonists (xanomeline, sabcomeline, talsaclidine, cevimeline) that produced dose-limiting cholinergic adverse events (salivation, gastrointestinal disturbance, diaphoresis) attributable to activation of peripheral M2 and M3 receptors, a limitation that terminated or constrained the clinical development of each of those compounds in the Alzheimer’s indication. The pharmacological characterization of CDD-0102 encompasses M1-selective receptor binding, stimulation of soluble APP-alpha (sAPPalpha) secretion from Chinese hamster ovary cells stably expressing human M1 receptors, neuroprotective activity in cell culture, brain penetration following systemic administration in rodents, oral bioavailability, and a favorable acute toxicity profile. In behavioral pharmacology, CDD-0102A administered intraperitoneally at doses of 0.03 to 1.0 mg/kg enhances delayed spontaneous alternation in a four-arm cross maze (a measure of spatial working memory) and facilitates strategy switching between place and visual-cue discriminations (a measure of cognitive flexibility), with both effects following a dose-dependent profile and occurring at doses below the threshold for salivation (approximately 0.3 mg/kg intraperitoneal for the minimum effective salivation dose, with an estimated ED50 for salivation of 2.0 mg/kg). More recent preclinical work has extended the pharmacological profile to autism spectrum disorder models, demonstrating that CDD-0102A attenuates stereotyped motor behaviors (self-grooming, digging) and modulates glutamate efflux in dorsolateral striatum of the BTBR T+ Itpr3tf/J mouse, a model of autism-relevant repetitive behavior and social deficit. The compound advanced through preclinical development with support from the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, which funded the IND-enabling studies including synthetic scale-up, formulation, pharmacokinetics, and toxicology. An Investigational New Drug (IND) application was filed with the United States Food and Drug Administration, and Phase 1 clinical testing was initiated. Published results from Phase 1 clinical evaluation have not appeared in the peer-reviewed literature as of the most recent monograph revision. The compound is not registered as a marketed medicine in any jurisdiction. This monograph reviews the chemistry, synthesis, and structural class of CDD-0102; the M1 muscarinic receptor pharmacology in molecular and functional detail; the preclinical evidence base across Alzheimer’s disease, cognitive flexibility, and autism-relevant endpoints; the available pharmacokinetic characterization; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety profile; and a comparative assessment of five M1 muscarinic receptor agonist candidates (xanomeline, sabcomeline, talsaclidine, AF267B, cevimeline) against CDD-0102 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1458Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Nicotinamide Riboside (NR)

Plain-language summaryIntrigue 70 / 100

Nicotinamide riboside (NR) is another NAD+ precursor that converts to NAD+ in the body. Sold as Niagen and Tru Niagen, it is one of the most extensively studied longevity supplements. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

46/100

Established NAD+ precursor with real clinical reach but declining novelty in a crowded precursor field

Look, NR had a genuinely important moment. When Bieganowski and Brenner nailed down the NRK1/NRK2 salvage route in 2004, it reframed the whole conversation about how cells maintain NAD+ pools outside the Preiss-Handler and de novo pathways. That was real. And the subsequent decade of work from the Brenner group at UC Irvine, the Auwerx lab in Lausanne, and others built a credible preclinical case across metabolic protection, cardiac function, neuroprotection, and stem cell compartments. We think that body of work holds up.

The issue is what 2024 and 2025 look like from a research priority standpoint. NR is no longer at the frontier. Its mechanism is textbook at this point: NR gets phosphorylated to NMN by NRK1 or NRK2, NMN gets adenylylated by the NMNATs, you get NAD+, and that feeds sirtuins, PARP1, and the rest of the canonical NAD+-dependent signaling machinery. Thats a clean, well-understood pathway. Clinical trials have confirmed that oral NR reliably elevates whole-blood NAD+ in humans, which is not nothing. But the functional endpoint story is more complicated. The AFFINITY-2 heart failure trial, the Parkinson cognition data, the skeletal muscle aging work, all of it shows consistent NAD+ elevation alongside effect sizes that range from modest to ambiguous on clinical endpoints. Replication exists but enthusiasm has cooled.

Where it gets more interesting is differentiation. NR sits in a crowded lane. NMN shares the same downstream pathway and has attracted serious investment from the Sinclair group and commercial players. NRH (dihydronicotinamide riboside) raises intracellular NAD+ faster and to higher levels in some cell models, which makes it a relevant competitor for bench work. CD38 inhibitors like 78c address NAD+ decline from the consumption side rather than the supply side, which is arguably more mechanistically targeted in aging contexts. NR is not clearly best-in-class on any single dimension right now, and that costs it on differentiation.

What we do like: the evidence quality is the highest in this class. Multiple sponsor-independent RCTs, reasonable sample sizes, multi-indication coverage. As a research tool, NR gives you clean NRK-pathway activation you can’t replicate with nicotinamide or niacin, which have different routing and very different tolerability profiles. For investigators specifically interrogating the NRK arm of NAD+ metabolism, it’s genuinely useful and not interchangeable. Honestly, that niche bench utility keeps the score from falling further. But for a lab deciding what to prioritize in 2025, NR is probably the compound you already understand rather than the one you’re excited to study.

Novelty

38

Mechanism promise

48

In-category differentiation

40

Evidence quality

58

Translational signal

50

Research bench value

48

Rationale NR is a chemically distinct entity from bare B3 vitamers and earns independent scoring via its NRK pathway pharmacology and multi-indication human evidence base; the generic vitamin cap does not bind. Scores are pulled down by modest novelty at this stage and real differentiation pressure from NMN, NRH, and CD38-inhibitor strategies that are gaining research attention.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pyridine nucleoside NAD+ precursor and vitamin B3 vitamer

A naturally occurring pyridine nucleoside form of vitamin B3 that serves as a direct precursor to nicotinamide adenine dinucleotide (NAD+) through the nicotinamide riboside kinase pathway, distinguished from other NAD+ precursors by direct cellular uptake, absence of flushing, and a growing clinical evidence base in aging, neurodegeneration, and cardiovascular function.

Abstract

Nicotinamide riboside (NR) is a pyridine nucleoside form of vitamin B3 and a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), the essential redox cofactor and sirtuin/PARP cosubstrate whose decline with aging is implicated in mitochondrial dysfunction, genomic instability, neurodegeneration, and metabolic disease. First identified as an NAD+ precursor in yeast by Bieganowski and Brenner in 2004 [1], NR is phosphorylated by the conserved nicotinamide riboside kinases NRK1 and NRK2 to nicotinamide mononucleotide (NMN), which is subsequently adenylylated by nicotinamide mononucleotide adenylyltransferases (NMNATs) to yield NAD+. This two-step pathway is independent of the Preiss-Handler and de novo biosynthetic routes and constitutes a distinct salvage mechanism for NAD+ repletion.

The compound attracted broad scientific attention following the 2012 demonstration by Canto, Houtkooper, Auwerx, and colleagues that dietary NR supplementation in mice activates SIRT1 and SIRT3, enhances mitochondrial oxidative metabolism, and protects against high-fat-diet-induced obesity and metabolic dysfunction [2]. Subsequent preclinical work established NR-mediated NAD+ repletion as protective in mouse models of dilated cardiomyopathy [3], noise-induced hearing loss, Alzheimer-like neurodegeneration, Parkinson disease [4], hepatic steatosis, muscular dystrophy, and age-related stem cell decline. In each case, the proposed mechanism centers on restoration of NAD+-dependent sirtuin and poly(ADP-ribose) polymerase activity in metabolically stressed tissues.

Translation to humans began with the Trammell et al. (2016) pharmacokinetic study demonstrating dose-dependent elevation of the blood NAD+ metabolome after single oral doses of 100, 300, and 1,000 mg in healthy volunteers [5]. The Martens et al. (2018) crossover trial in healthy middle-aged and older adults confirmed that chronic NR supplementation at 1,000 mg daily for six weeks is well tolerated, elevates whole-blood NAD+ by approximately 60 percent, and produces a trend toward reduced systolic blood pressure and aortic stiffness [6]. The Conze, Brenner, and Kruger (2019) eight-week randomized trial in 140 healthy overweight adults established dose-dependent (100, 300, 1,000 mg daily) and sustained NAD+ elevation with no detectable adverse effect on hepatic, renal, or lipid parameters [7]. The Elhassan et al. (2019) study demonstrated that NR augments the aged human skeletal muscle NAD+ metabolome and induces anti-inflammatory transcriptomic signatures [8]. More recently, the NADPARK trial (Brakedal et al. 2022) showed that NR at 1,000 mg daily for 30 days is well tolerated in newly diagnosed Parkinson disease patients, increases cerebral NAD levels measured by phosphorus magnetic resonance spectroscopy, and is associated with altered cerebral metabolism and mild clinical improvement in a subset of responders [4]. The NR-SAFE trial (2023) extended the safety assessment to 3,000 mg daily for 30 days in Parkinson disease patients, confirming tolerability and up to five-fold blood NAD+ elevation without methyl donor depletion [9].

Despite consistent pharmacodynamic evidence that oral NR elevates NAD+ in blood, muscle, and brain, clinically meaningful efficacy endpoints have proven elusive in most completed trials. NR has not demonstrated significant effects on insulin sensitivity, whole-body glucose metabolism, or skeletal muscle mitochondrial bioenergetics in randomized controlled trials in obese or older adults [10, 11]. Cognitive endpoints have not reached significance in trials of mild cognitive impairment [12]. The compound is therefore positioned as a well-tolerated NAD+ repletion agent with strong preclinical rationale, consistent pharmacodynamic activity, and an incomplete clinical efficacy record that awaits adequately powered Phase 2 and Phase 3 trials in disease-specific populations.

Nicotinamide riboside chloride is marketed as the dietary supplement Niagen (ChromaDex/Niagen Bioscience) and has received Generally Recognized as Safe (GRAS) status from the United States Food and Drug Administration for use as a vitamin B3 source in foods [13], as well as two successful New Dietary Ingredient notifications for use in dietary supplements. The compound is not approved as a drug for any indication. This monograph reviews the chemistry, biosynthetic pathway, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, stack interactions, adverse-event profile, and a comparative assessment of five NAD+ precursor and booster candidates against NR on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1485Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
BAM15

Our opinion on this compoundNovel, promising

62/100

Mitochondrial-selective uncoupler with compelling metabolic preclinical data but no human trials yet

Look, the classical uncoupler problem is straightforward: DNP works, DNP also kills you. The mechanism is compelling but plasma membrane depolarization is a hard ceiling on the whole class. BAM15 is the first compound to credibly solve that problem at the scaffold level. The oxadiazolopyrazine core allows mitochondrial-selective proton gradient dissipation without collapsing the plasma membrane potential, and thats not a minor technical footnote. It’s the thing that makes a therapeutic uncoupler program viable at all.

The Kenwood 2014 phenotypic screen at UVA/Virginia Tech was searching for exactly this property, and BAM15 emerged as the lead hit. Alexopoulos et al. (2020) is where the metabolic pharmacology really landed: 100 mg/kg/day oral in HFD C57BL/6J mice reversed diet-induced obesity, cut hepatic triglycerides by roughly 75 percent, and improved insulin sensitivity on hyperinsulinemic-euglycemic clamp, without touching food intake or lean mass. That’s the profile you want. The head-to-head in db/db female mice is genuinely striking: BAM15 and calorie restriction outperformed semaglutide, niclosamide ethanolamine, and rosiglitazone on body weight and liver steatosis endpoints. That kind of direct comparator data gets investigators’ attention.

What we like beyond the metabolics: the preclinical breadth here is unusual for a compound still sitting on the shelf. Sepsis survival benefit 12 hours post cecal ligation and puncture. AML cell selectivity with ROS-mediated apoptosis sparing normal hematopoietic cells. Atherosclerosis suppression in ApoE-knockout mice through AMPK and NF-kappaB/NLRP3 suppression. Sarcopenia signal in aged mice with preserved skeletal muscle contractility. The AMPK/PGC-1alpha axis and mitochondrial dynamics connect these indications in a biologically coherent way, not just target-hunting.

What we dont like: no human data, at all. BAM15 has been in preclinical development since 2014 and hasn’t reached a phase 1 trial. The short half-life of 1.7 hours in mice and heavy hepatic distribution raise real PK questions that haven’t been answered in people. Hepatic selectivity that’s a feature for MASH could be a constraint for CNS or skeletal muscle indications. The history of uncouplers in the clinic is not reassuring, and translational risk for this class is genuinely elevated even with the improved safety index.

As a bench tool, though, BAM15 is about as useful as it gets for mitochondrial biology. It lets you cleanly dissect mitochondrial membrane potential from plasma membrane potential in ways that FCCP, at effective concentrations, simply cannot do safely. That probe utility is independent of the therapeutic story. We think BAM15 belongs in serious metabolic and mitochondrial research programs right now. But the 2014-to-still-no-IND timeline is a signal worth sitting with before you center a program on it.

Novelty

65

Mechanism promise

80

In-category differentiation

72

Evidence quality

42

Translational signal

32

Research bench value

70

Rationale BAM15 earns strong mechanism and differentiation scores for credibly solving the classical uncoupler toxicity problem through mitochondrial-selective proton gradient dissipation, backed by multi-indication preclinical breadth across metabolic, sepsis, oncology, and aging models; the overall is held back by zero human clinical data and a 2014 discovery date that limits novelty credit relative to bleeding-edge candidates.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mitochondria-selective protonophore uncoupler of oxidative phosphorylation

A synthetic oxadiazolopyrazine-scaffold mitochondrial protonophore distinguished from classical uncouplers by selective dissipation of the inner mitochondrial membrane proton gradient without depolarization of the plasma membrane, conferring potent metabolic enhancement with markedly reduced cytotoxicity in preclinical models of obesity, insulin resistance, hepatic steatosis, sepsis, and cancer.

Abstract

BAM15 (N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a synthetic small-molecule mitochondrial protonophore first identified in a 2014 phenotypic screen by Kenwood et al. at the University of Virginia and Virginia Tech for compounds that uncouple mitochondrial oxidative phosphorylation without depolarizing the plasma membrane [1]. The compound dissipates the electrochemical proton gradient across the inner mitochondrial membrane, thereby uncoupling electron transport from adenosine triphosphate (ATP) synthesis and increasing substrate oxidation and energy expenditure. Unlike the classical protonophore uncouplers 2,4-dinitrophenol (DNP) and carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), BAM15 selectively targets the mitochondrial membrane and does not collapse the plasma membrane potential at effective uncoupling concentrations, a property that confers a substantially wider therapeutic index and reduced cytotoxicity in cultured cells and in vivo [1, 2]. The compound is orally bioavailable in mice (67 percent oral bioavailability, Cmax 8.2 micromolar, t1/2 1.7 hours) with primary distribution to the liver, supporting hepatic metabolic applications [3]. In C57BL/6J mice fed a high-fat diet, BAM15 administered at 100 mg/kg/day by oral gavage reversed diet-induced obesity, decreased body fat mass without altering food intake or lean body mass, reduced hepatic triglycerides by approximately 75 percent, decreased inflammatory lipids, and improved whole-body insulin sensitivity as demonstrated by hyperinsulinemic-euglycemic clamp [3]. In a head-to-head comparison in female db/db mice, BAM15 and calorie restriction improved body weight and liver steatosis to levels superior to semaglutide, niclosamide ethanolamine (NEN), and rosiglitazone, while BAM15, semaglutide, and rosiglitazone completely restored glucose tolerance [4]. These metabolic effects are mediated through sustained activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), promoting fatty acid oxidation, glucose uptake, and mitochondrial biogenesis [2, 5]. Beyond metabolic disease, BAM15 has demonstrated preclinical efficacy in acute kidney injury and sepsis (reducing mortality even when administered 12 hours after cecal ligation and puncture in mice) [6], in acute myeloid leukemia (inhibiting AML cell proliferation and inducing reactive oxygen species-mediated apoptosis with selectivity over normal cells) [7], in sarcopenic obesity (preserving skeletal muscle contractility and mitochondrial respiration in aged mice) [8, 9], in atherosclerosis (suppressing western diet-induced plaque formation in ApoE-knockout mice through AMPK activation and NF-kappaB/NLRP3 inflammasome suppression) [10, 11], and in vascular smooth muscle relaxation [5]. Safety pharmacology in rodents has demonstrated no alteration of body temperature, food intake, lean body mass, or standard hematological and biochemical markers of toxicity at effective metabolic doses [3]. BAM15 has not entered human clinical trials as of the most recent monograph revision. The compound is supplied as a research-grade material by multiple chemical suppliers at greater than 98 percent purity and is not approved by any regulatory authority for therapeutic use. This monograph documents the chemistry, synthesis, discovery history, molecular pharmacology, pharmacokinetics, preclinical evidence base across metabolic, inflammatory, oncologic, and aging indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment against five alternative mitochondrial uncouplers.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1470Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
EPI-743

Our opinion on this compoundEstablished, active research

58/100

First-in-class 15-LO inhibitor with a live ferroptosis connection, real but contested clinical data in rare mitochondrial disease

Look, EPI-743 is one of the more interesting compounds to come out of the rare mitochondrial disease space, and we think most researchers in redox biology will find it underappreciated once you dig into what’s actually happening mechanistically. The compound is not vitamin E. It’s a synthetic para-benzoquinone that was built from the alpha-tocotrienol chromanone ring and then optimized in a phenotypic screen using BSO-induced oxidative cell death as the readout. The result is something that behaves as a high-affinity substrate for NQO1 and, separately, as a selective inhibitor of 15-lipoxygenase. That second part matters enormously right now.

Fifteen-lipoxygenase is one of the two enzymes most investigators point to when you ask them how ferroptotic lipid peroxidation propagates when GPX4 is compromised. The GPX4/15-LO/ferroptosis axis is probably the most active area of cell death biology since the original ferroptosis papers in 2012, and vatiquinone is a reasonably characterized, orally bioavailable small molecule that hits it. Thats not a trivial thing. The field has been short on clean probes for this target, and EPI-743’s combination of direct 15-LO inhibition plus NQO1-driven glutathione replenishment gives it a dual redox profile that’s genuinely difficult to replicate with other tool compounds.

The clinical picture is messier. The early open-label work in Leigh syndrome and Leber hereditary optic neuropathy was small and uncontrolled, but the signals were real and consistent enough that Edison, then BioElectron, then PTC Therapeutics all put serious money behind it, culminating in the roughly $210 million acquisition and the Phase 3 MOVE-FA trial in Friedreich ataxia. MOVE-FA is where things get complicated. The primary endpoint, mFARS change from baseline in the primary analysis population, came in at p = 0.14. The upright stability subscale hit p = 0.021. The per-protocol population cleared the primary threshold. The long-term extension showed 3.7 points versus matched natural history at 144 weeks, which is roughly a 50 percent slowing of progression. That’s not nothing, but it wasn’t enough for the FDA, which issued a Complete Response Letter in 2025 asking for additional efficacy data. Omaveloxolone got the approval in Friedreich ataxia first.

Here’s the thing though: the CRL is a drug development setback, not a scientific indictment of the mechanism. The ferroptosis angle is if anything gaining traction in the published literature, not losing it. For investigators working on mitochondrial oxidative stress, ferroptosis in neurodegeneration, or GPX4-pathway biology, vatiquinone remains a well-characterized probe with a defined pharmacokinetic profile and a clean long-term safety record across more than 500 patients. What we like is that this is one of the few non-lipid-based 15-LO inhibitors with real clinical pharmacokinetics. What we don’t like is that replication outside the Edison/PTC development program is thin, and the primary endpoint failure means regulatory validation didn’t come through. Interesting compound. Genuinely useful in the right research program. Just don’t go in expecting a slam dunk in the evidence column.

Novelty

60

Mechanism promise

72

In-category differentiation

58

Evidence quality

45

Translational signal

47

Research bench value

60

Rationale Vatiquinone is a synthetic para-benzoquinone, not generic vitamin E, and the vitamin cap does not apply. Its first-in-class 15-lipoxygenase inhibition mechanism sits squarely inside the hottest oxidative cell death biology right now (ferroptosis/GPX4 axis), earning real mechanism and bench scores; however, the Phase 3 MOVE-FA primary endpoint miss and the FDA Complete Response Letter substantially limit both the evidence and translational scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Para-benzoquinone 15-lipoxygenase inhibitor and redox-active cytoprotectant derived from alpha-tocotrienol quinone

A synthetic vitamin E-derived para-benzoquinone developed by Edison Pharmaceuticals as a potent inhibitor of 15-lipoxygenase and augmenter of intracellular glutathione biosynthesis, advanced through clinical evaluation in Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other inherited mitochondrial respiratory chain diseases.

Abstract

EPI-743, now designated vatiquinone (INN) and previously referred to by the development codes PTC-743 and alpha-tocotrienol quinone, is a synthetic para-benzoquinone derived from the chromanone ring system of vitamin E (alpha-tocotrienol) that was identified in a phenotypic screen for small molecules capable of preventing oxidative cell death induced by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and therefore of de novo glutathione biosynthesis. The compound is approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease and Friedreich ataxia patient fibroblasts in oxidative stress assays, a potency differential attributed to its capacity to serve as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) and thereby to replenish reduced intracellular glutathione and stabilize cellular redox balance. The mechanistic target has subsequently been identified as 15-lipoxygenase (15-LO), an oxidoreductase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids under conditions of glutathione depletion or glutathione peroxidase 4 (GPX4) inactivation, a process now recognized as the lipid peroxidation arm of ferroptotic cell death. Vatiquinone is therefore classified as a first-in-class selective inhibitor of 15-lipoxygenase with secondary redox-modulatory activity through NQO1-dependent glutathione replenishment. The compound was discovered at Edison Pharmaceuticals (Mountain View, California), a company founded by Guy Miller and subsequently renamed BioElectron Technology Corporation in 2017. PTC Therapeutics acquired substantially all of BioElectron’s assets, including the vatiquinone program, in October 2019 for approximately $210 million. The clinical development program has spanned multiple inherited mitochondrial diseases and related conditions characterized by oxidative stress, mitochondrial dysfunction, and ferroptotic cell death. Open-label and emergency-protocol studies conducted between 2011 and 2017 evaluated EPI-743 in Leigh syndrome (Martinelli et al. 2012, ten pediatric patients, statistically significant reversal of disease progression on the Newcastle Pediatric Mitochondrial Disease Scale), in Leber hereditary optic neuropathy (Sadun et al. 2012, five patients, arrest of disease progression and reversal of visual loss in four of five subjects), in a heterogeneous cohort of genetically confirmed mitochondrial respiratory chain diseases (Enns et al. 2012, fourteen patients, clinical improvement in eleven of twelve survivors), and in Pearson syndrome. A Phase 2 study in Friedreich ataxia demonstrated safety and tolerability over two years. The pivotal registration-directed program is the Phase 3 MOVE-FA trial, a randomized, placebo-controlled, 72-week study in 146 pediatric and adult patients with Friedreich ataxia. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population (p = 0.14), though statistically significant effects were observed on the pre-specified upright stability subscale (p = 0.021) and in the per-protocol population (p < 0.05). Long-term extension data demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry at 144 weeks, representing a 50 percent slowing of disease progression over three years. PTC Therapeutics submitted a New Drug Application to the United States Food and Drug Administration, which granted Priority Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter, indicating that additional efficacy data would be required to support approval. Pharmacokinetics are characterized by oral absorption with an effective half-life of approximately 9 hours, dose-proportional exposure across oral doses of 200 to 1,400 mg, CYP3A4-mediated hepatic metabolism, and lipophilic distribution consistent with the vitamin E-derived chemical structure. The compound is administered three times daily with food to enhance bioavailability. The safety profile across more than 500 patients and treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies. This monograph reviews the chemistry, synthesis, and structural pharmacology of EPI-743; the 15-lipoxygenase inhibition and NQO1-dependent redox mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other mitochondrial diseases; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative mitochondrial cytoprotectant or antioxidant compounds (idebenone, omaveloxolone, coenzyme Q10, elamipretide, and alpha-tocopherol) against EPI-743 on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1468Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Spermidine

Plain-language summaryIntrigue 76 / 100

Spermidine is a small natural polyamine found in wheat germ, aged cheese, and other foods. It induces autophagy (the cellular cleanup process) and has been linked to longevity in multiple species. Often sold as a longevity supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

55/100

Endogenous polyamine with a genuine EP300-autophagy mechanism and epidemiological grounding, but clinical data still maturing

Look, spermidine is not a new molecule. Van Leeuwenhoek found crystals of it in human semen in 1678, and the biosynthetic pathway from putrescine through spermidine synthase has been in biochemistry textbooks for decades. What reframed this compound as a serious research target was Eisenberg et al. in Nature Cell Biology in 2009, where Frank Madeo’s group at Graz showed exogenous spermidine extended lifespan across multiple model organisms by inducing macroautophagy, and that the operative mechanism runs through inhibition of EP300 acetyltransferase rather than through mTOR. That distinction is not trivial. Rapamycin-mediated mTOR suppression carries immunosuppressive liability and disrupts nutrient sensing broadly. EP300 inhibition is a narrower, more specific route to autophagy induction, and its full pharmacological map is still incomplete.

The eIF5A hypusination story adds a second genuinely interesting layer. Spermidine is the obligate aminopropyl donor for hypusination of eukaryotic translation initiation factor 5A, and that modification turns out to be required for efficient translation of a defined mRNA subset enriched in autophagy regulators and mitochondrial biogenesis factors. So the mechanism isnt just toggling one pathway; it’s shaping translational fidelity for a functionally coherent mRNA class. Nothing else in the longevity toolbox hits that same target, which matters for differentiation. The anti-inflammatory and chromatin-level effects are real but less mechanistically distinctive.

The evidence base is better than most compounds in the geroprotective category without being fully mature. The Bruneck cohort data, correlating 20-year dietary spermidine intake with reduced cardiovascular and all-cause mortality, is epidemiological but well-controlled and replicated in direction by Austrian and Scandinavian cohort work. The RCTs are real: Schwarz et al. 2022 and the earlier Wirth-group pilot both show cognitive signal in older adults, with effect sizes on objective and subjective memory measures that are modest but statistically sound. Multi-lab preclinical. This is not a single-consortium story, which already puts it ahead of BPC-157 or Epitalon.

We think the honest peer comparators are urolithin A and SS-31: all three make a mitochondrial quality control argument with small but legitimate clinical data. Spermidine has more epidemiological grounding than either. Where it trails rapamycin is potency and preclinical depth; rapamycin remains the dominant autophagy and mTOR probe regardless of clinical risk profile. What we like about spermidine is the mechanism specificity and the bench utility for studying EP300-dependent autophagy induction as a caloric restriction mimetic. What we dont like: the RCTs stay small-N, effect sizes are modest, and the relative contribution of hypusination versus EP300 inhibition to net in vivo effects remains unmapped. A 55 reflects a compound doing real, replicable science in a well-motivated research space, but one that hasnt yet produced the kind of effect-size or mechanistic clarity that would make it genuinely high-priority over better-powered comparators.

Novelty

42

Mechanism promise

67

In-category differentiation

55

Evidence quality

52

Translational signal

55

Research bench value

60

Rationale Spermidine scores meaningfully on mechanism because the EP300 acetyltransferase inhibition route to autophagy is distinct from mTOR suppression and the eIF5A hypusination story adds genuine translational complexity; novelty is moderate given decades of polyamine biochemistry, and the RCT base is multi-lab but small-N, keeping evidence and translational axes from carrying the score higher.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Naturally occurring triamine polyamine and caloric restriction mimetic with autophagy-inducing, cardioprotective, and geroprotective activity

An endogenous polyamine present in all eukaryotic cells, distinguished among geroprotective candidates by physiological autophagy induction via EP300 acetyltransferase inhibition, eIF5A hypusination, and epidemiologically validated cardiovascular and cognitive protection in aging populations.

Abstract

Spermidine (N-(3-aminopropyl)butane-1,4-diamine) is a naturally occurring triamine polyamine present in all living cells and in the human diet, principally from wheat germ, soybeans, fermented foods, and aged cheeses. First observed as a crystalline component of human semen by Antonie van Leeuwenhoek in 1678, spermidine was structurally characterized in the early twentieth century and subsequently identified as a central metabolite in polyamine biosynthesis, formed by the transfer of an aminopropyl group from decarboxylated S-adenosylmethionine to putrescine by the enzyme spermidine synthase. The compound participates in multiple essential cellular processes including chromatin structure modulation, translational regulation through hypusination of eukaryotic translation initiation factor 5A (eIF5A), cell proliferation, and the induction of macroautophagy.

The geroprotective potential of spermidine was established in a series of investigations beginning with the Eisenberg et al. (2009) demonstration that exogenous spermidine extends chronological lifespan in yeast, nematodes, and flies through autophagy-dependent mechanisms [1]. The molecular basis for autophagy induction was subsequently characterized as inhibition of the acetyltransferase EP300 (p300), resulting in hypoacetylation of core autophagy proteins (ATG5, ATG7, ATG12, and LC3) and convergent deacetylation of cytoplasmic proteins that parallels the acetylproteome shifts produced by caloric restriction and by other caloric restriction mimetics [2, 3]. Spermidine thereby occupies a mechanistically distinct position among autophagy inducers: it acts through acetyltransferase inhibition rather than through mTOR suppression (rapamycin), AMPK activation (metformin), or sirtuin activation (resveratrol).

The landmark Eisenberg et al. (2016) study in Nature Medicine demonstrated that oral spermidine supplementation extends lifespan in mice, reduces cardiac hypertrophy, preserves diastolic function in aged animals, delays progression to heart failure in salt-sensitive hypertensive rats, and enhances cardiac autophagy, mitophagy, and mitochondrial respiration in an ATG5-dependent manner [4]. Epidemiological analysis of the Bruneck Study cohort (n = 829, 20-year follow-up) within the same report identified a significant inverse association between dietary spermidine intake and cardiovascular mortality, all-cause mortality, and cancer-related mortality, with the highest-intake tertile exhibiting a risk reduction comparable to approximately 5.7 years of aging [4, 5]. These findings were extended by Kiechl et al. (2018), who confirmed the inverse relationship between dietary spermidine and mortality in a larger epidemiological analysis [5].

Clinical investigation of spermidine has advanced through several randomized controlled trials. The SmartAge trial (Wirth et al. 2018, 2022) evaluated spermidine-rich wheat germ extract supplementation in older adults with subjective cognitive decline; a 3-month pilot study reported modest memory improvement, while a 12-month Phase IIb trial did not demonstrate significant modification of memory performance or biomarkers at the studied dose [6, 7]. The POLYCAD trial (NCT05128331), a Danish randomized double-blind placebo-controlled study of 24 mg/day spermidine in 187 elderly patients with coronary artery disease, completed enrollment in 2025 and represents the first dedicated cardiovascular outcomes trial for spermidine [8]. Additional trials have examined metabolic responses to spermidine supplementation (NCT05459961) and dose-escalation safety in aging populations.

Pharmacokinetic studies have revealed that dietary spermidine is rapidly absorbed from the intestinal lumen but is subject to extensive presystemic conversion to spermine, resulting in minimal elevation of circulating spermidine concentrations following oral supplementation at doses up to 40 mg/day [9, 10]. This observation suggests that the biological effects of oral spermidine may be mediated through local gastrointestinal and first-pass hepatic mechanisms, through polyamine interconversion in target tissues, or through modulation of gut microbiota-derived polyamine pools rather than through systemic plasma exposure.

Spermidine supplementation has demonstrated a favorable safety profile in all completed human studies. No serious adverse events attributable to the compound have been reported. The European Food Safety Authority authorized spermidine-rich wheat germ extract as a Novel Food in 2021 with a recommended upper intake of 6 mg/day of spermidine [11]. Higher doses (up to 40 mg/day of purified spermidine for 28 days) have been evaluated without significant adverse effects in healthy older men [10]. This monograph reviews the chemistry, biosynthesis, and dietary sources of spermidine; the molecular pharmacology of autophagy induction, eIF5A hypusination, and anti-inflammatory signaling; pharmacokinetics; the preclinical and clinical evidence base across cardiovascular, cognitive, and geroprotective applications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signal; and a comparative assessment of five geroprotective and autophagy-inducing compounds (rapamycin, resveratrol, nicotinamide mononucleotide, urolithin A, and metformin) against spermidine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1474Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Fisetin

Plain-language summaryIntrigue 78 / 100

Fisetin is a natural flavonoid found in strawberries and apples that selectively kills senescent cells (a senolytic). Mayo Clinic researchers identified it in screens looking for natural compounds with senolytic activity. Clinical trials are ongoing. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

58/100

Leading dietary senolytic with real clinical infrastructure but human efficacy still unproven

Fisetin had a genuinely compelling moment in 2017-2018. The Zhu et al. screen at Mayo and the Yousefzadeh follow-up showing late-life oral dosing extended median and maximum lifespan in wild-type mice were real milestones. Wild-type, not transgenic, dosed late in life. That’s harder to dismiss than most aging biology data. That result earned fisetin a serious senolytic franchise, and it’s held enough to generate multiple Kirkland-lab clinical trials including the AFFINITY frailty study and STOP-Sepsis.

The mechanism is legitimately interesting. Fisetin hits Bcl-2 family members to drive selective apoptosis in senescent cells, which is exactly the definition of a senolytic rather than a generic cytotoxic. Layered on that: PI3K/Akt/mTOR suppression via TSC2 activation, SIRT1-dependent NF-kappaB silencing that dampens the SASP, and Nrf2-driven antioxidant upregulation. The Maher lab at Salk added a distinct neuroprotection angle via FASN inhibition and lipid peroxidation reduction. Multiple pharmacological personalities in one flavonol. Thats a legitimately useful probe profile for anyone working senescence biology or neuroinflammation.

Where we pull back is the translational column. Preclinical replication is solid across multiple labs. But clinical efficacy data isn’t published from the major trials yet. AFFINITY and STOP-Sepsis are ongoing. CMS121, the Maher group’s optimized fisetin derivative, completed Phase 1 in 2025 with acceptable tolerability and PK, but thats safety not efficacy. The gap between strong preclinical and demonstrated senolytic effect in aging humans is exactly where promising flavonoids have historically stalled.

Differentiation is the other constraint. Dasatinib plus quercetin is still the reference senolytic combination with more clinical infrastructure behind it. Fisetin’s value as a dietary-source senolytic with a cleaner safety profile is scientifically defensible, but not yet demonstrated superior. It occupies a real but contested middle ground. We think the CMS121 derivative is actually the more interesting story right now, but the parent scaffold earns its place in any serious senolytic research program.

Bench value is solid: useful probe for Bcl-2 dynamics in senescent cells, SIRT1/NF-kappaB crosstalk, and the bioavailability problem itself generates real formulation research, with nanocochleate and liposomal approaches showing 10- to 140-fold PK enhancement in preclinical models. Honestly, 58 captures where this sits: real mechanism, real clinical infrastructure, multi-lab preclinical, but human efficacy unproven and category leadership not yet established.

Novelty

60

Mechanism promise

68

In-category differentiation

60

Evidence quality

55

Translational signal

45

Research bench value

58

Rationale Fisetin scores as established-active: multi-lab preclinical, a credible Kirkland-lab clinical trial program, and a genuine multi-pathway senolytic mechanism earn mid-range scores across all axes, but pending clinical efficacy readouts and second-tier differentiation versus dasatinib plus quercetin hold the overall at 58. The novel-indication exception (senolytic application is a post-2017 discovery with real clinical signal) prevents any OTC food/herb cap from binding.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Flavonol polyphenol with senolytic, anti-inflammatory, and neuroprotective activity

A naturally occurring 3,7,3′,4′-tetrahydroxyflavone identified as one of the most potent flavonoid senolytics, with convergent activity across PI3K/Akt/mTOR inhibition, SIRT1 activation, NF-kappaB suppression, and Nrf2-mediated antioxidant defense, positioned at the intersection of aging biology, neurodegeneration, and cancer chemoprevention research.

Abstract

Fisetin (3,7,3′,4′-tetrahydroxyflavone) is a bioactive flavonol found at highest dietary concentration in strawberries and at lower levels in apples, persimmons, grapes, onions, and cucumbers. First isolated from the heartwood of Venetian sumac (Cotinus coggygria) in the late nineteenth century and characterized as a plant pigment, fisetin remained a minor flavonoid of limited pharmacological interest until convergent twenty-first-century discoveries established it as a multi-target agent active across the principal molecular pathways of cellular senescence, neurodegeneration, inflammation, and oncogenesis. The compound was identified as a potent senolytic in the landmark Zhu et al. (2017) screen at the Mayo Clinic Robert and Arlene Kogod Center on Aging, and the subsequent Yousefzadeh et al. (2018) demonstration that late-life oral fisetin administration extended median and maximum lifespan in wild-type mice while reducing senescence-associated markers in multiple tissues positioned it as the leading dietary flavonoid candidate for translational senolytic therapy [1, 2]. Mechanistically, fisetin operates through a convergent multi-pathway pharmacology: it inhibits PI3K/Akt/mTOR signaling by direct suppression of PI3K catalytic and regulatory subunit expression and by activation of the mTOR repressor TSC2 through concurrent AMPK phosphorylation; it activates SIRT1-dependent deacetylation cascades that suppress NF-kappaB transcriptional activity and the senescence-associated secretory phenotype (SASP); it induces Nrf2 nuclear translocation and downstream phase II antioxidant enzyme expression; and it modulates the Bcl-2 family balance toward pro-apoptotic signaling selectively in senescent cells [3, 4, 5]. The neuroprotective profile has been extensively characterized by the Maher laboratory at the Salk Institute for Biological Studies, where fisetin and its optimized derivative CMS121 have demonstrated efficacy in transgenic Alzheimer’s disease mouse models through reduction of lipid peroxidation via fatty acid synthase (FASN) inhibition, suppression of neuroinflammatory cascades, and maintenance of glutathione homeostasis [6, 7]. CMS121 completed a Phase 1 clinical trial in 2025, with single doses up to 1800 mg and repeat doses up to 900 mg per day for 7 days demonstrating acceptable tolerability and favorable pharmacokinetic parameters in healthy volunteers [8]. The anticancer pharmacology spans preclinical efficacy in prostate, breast, colorectal, lung, melanoma, pancreatic, and bladder cancer models, principally through cell cycle arrest at G2/M and G1/S checkpoints, mitochondrial apoptosis induction, and suppression of epithelial-mesenchymal transition and matrix metalloproteinase expression [9, 10]. Clinical translation is constrained by the poor oral bioavailability characteristic of hydroxylated flavonols: fisetin undergoes rapid and extensive phase II conjugation (glucuronidation and sulfation) in the intestinal epithelium and liver, producing low systemic free flavonol concentrations after oral dosing; multiple formulation strategies (nanocochleates, liposomes, nanoemulsions, hybrid hydrogels) have demonstrated 10- to 140-fold bioavailability enhancement in preclinical and early human pharmacokinetic studies [11, 12]. Clinical trials led by the Kirkland laboratory at Mayo Clinic are evaluating fisetin at oral doses of 20 mg/kg per day for senolytic indications including frailty in aging (AFFINITY trial, NCT03675724), COVID-19 in skilled nursing facilities, and sepsis in elderly patients (STOP-Sepsis, NCT05758246) [13, 14]. This monograph reviews the chemistry, natural sourcing, and structural pharmacology of fisetin; the multi-pathway molecular mechanism across senescence, inflammation, neuroprotection, and oncogenesis; the pharmacokinetic limitations and formulation solutions; the preclinical evidence base across aging, neurodegeneration, and cancer; the clinical trial landscape; sourcing and quality verification for research applications; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five senolytic or flavonoid candidates against fisetin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1481Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
AF710B

Our opinion on this compoundNovel, promising

62/100

Dual allosteric M1 and sigma-1R agonist with multi-lab disease-modifying preclinical and confirmed Phase 1 human safety

Look, AF710B is one of the more intellectually interesting compounds in the cholinergic AD space right now, and the dual-target mechanism is the reason. Earlier orthosteric M1 agonists from the same Fisher group at IIBR, AF267B and cevimeline, showed real procognitive and anti-amyloidogenic activity in preclinical work but kept running into the same wall: insufficient M1 selectivity and dose-limiting cholinergic toxicity. AF710B sidesteps that wall by working allosterically, potentiating endogenous acetylcholine at the M1 receptor rather than competing with it, which preserves the downstream ERK1/2 and CREB signaling you want while avoiding the cardiovascular and GI adverse effects that crippled the earlier series. The selectivity screen at 10 micromolar across 83 receptors, ion channels, and transporters came back clean. Thats a genuinely useful pharmacological profile, especially compared to xanomeline, which required coadministration with a peripheral antimuscarinic just to become tolerable.

The sigma-1 receptor piece is what keeps this from being just a cleaner orthosteric. Sigma-1R is an ER chaperone concentrated at the mitochondria-associated membrane, and its activation does several things simultaneously: normalizes calcium transfer between the ER and mitochondria, modulates the unfolded protein response, suppresses neuroinflammation through antiapoptotic cascades. The dendritic spine rescue data in presenilin-1 and APP knock-in neuronal cultures is worth noting here. Mushroom spine loss is one of the earliest structural correlates of synaptic dysfunction in AD models, and recovering that population via sigma-1R agonism points at a neuroprotective axis independent of the cholinergic one. Thats two mechanistically distinct handles on AD pathology in a single molecule.

The preclinical case is multi-lab and, honestly, unusually clean for this space. Fisher et al. 2016 in 3xTg-AD mice showed simultaneous reduction in BACE1, GSK3-beta activity, amyloid plaque, phospho-tau, and neuroinflammatory markers alongside cognitive improvement in the Morris water maze. Hall et al. 2018 replicated the core findings in the McGill-R-Thy1-APP rat at 10 micrograms per kilogram oral, and the effects persisted through a five-week drug washout. Thats the disease-modification signal, not symptomatic masking. Bhatt et al. 2024 rounded it out with early-treatment prevention data in the same rat line. Three groups, two species, two transgenic models. Not a single-consortium story.

Where we dont get excited is the clinical side. Phase 1 in 42 healthy volunteers confirmed safety and linear, dose-proportional PK with a half-life around 3.5 hours. The Phase 2 in schizophrenia (ANAVEX3-71-SZ-001) reported positive topline results in late 2025, specifically GFAP reduction and encouraging EEG biomarker trends, which is interesting but its a different indication with soft endpoints. No AD Phase 2 exists. The FTD orphan designation signals regulatory awareness, not clinical proof. For a bench-scale investigator, what’s here is a well-characterized allosteric M1/sigma-1R dual probe with clean selectivity data and enough preclinical depth to support serious mechanistic work. The outstanding question is whether any of this translates in AD patients, and that answer doesnt exist yet.

Novelty

68

Mechanism promise

78

In-category differentiation

65

Evidence quality

50

Translational signal

42

Research bench value

58

Rationale The allosteric M1 selectivity plus sigma-1R chaperone dual mechanism is genuinely distinctive from orthosteric predecessors and current muscarinic competitors; multi-lab, two-species preclinical with disease-modification signal and Phase 1 PK confirmation justify solid novel-promising placement, but absent any AD-indication Phase 2 data the translational score stays modest.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Allosteric M1 muscarinic acetylcholine receptor agonist and sigma-1 receptor agonist with disease-modifying preclinical efficacy in Alzheimer’s disease models

A dual-target allosteric M1 muscarinic and sigma-1 receptor agonist developed at the Israel Institute for Biological Research and advanced by Anavex Life Sciences as ANAVEX 3-71, distinguished from earlier orthosteric muscarinic agonists by allosteric M1 selectivity, picomolar-range potency, sigma-1 chaperone engagement, and disease-modifying activity across amyloid, tau, and neuroinflammatory pathologies in transgenic rodent models of Alzheimer’s disease.

Abstract

AF710B (ANAVEX 3-71) is a highly potent and selective allosteric agonist of the M1 subtype of the muscarinic acetylcholine receptor (M1 mAChR) and a concurrent agonist of the sigma-1 receptor (sigma-1R), first reported by Fisher et al. (2016) in Neurodegenerative Diseases as a next-generation candidate for cognitive enhancement and disease modification in Alzheimer’s disease [1]. The compound emerged from a decades-long medicinal chemistry program at the Israel Institute for Biological Research (IIBR) that previously produced the orthosteric M1 agonists AF102B (cevimeline, approved for Sjogren’s syndrome), AF267B, and AF292, each of which demonstrated procognitive and anti-amyloidogenic activity in preclinical and early clinical settings but was limited by insufficient M1 selectivity, dose-limiting cholinergic adverse events, or both. AF710B was designed to overcome these limitations through an allosteric mechanism of M1 receptor engagement: at nanomolar concentrations the compound potentiates the binding and efficacy of the endogenous agonist acetylcholine (and of the reference orthosteric agonist carbachol) at the M1 receptor, amplifying downstream signaling through phospho-ERK1/2 and phospho-CREB pathways without producing the gastrointestinal and cardiovascular cholinergic toxicity that constrained the earlier orthosteric series [1, 2]. Selectivity screening at 10 micromolar against 83 additional G-protein-coupled receptors, ion channels, and transporters produced no significant off-target hits, establishing a pharmacological selectivity profile substantially cleaner than that of xanomeline and other earlier M1-preferring agonists [1]. The sigma-1 receptor agonism adds a second, mechanistically independent neuroprotective axis. Sigma-1R is an endoplasmic reticulum chaperone protein concentrated at the mitochondria-associated endoplasmic reticulum membrane (MAM), where it regulates calcium transfer between the endoplasmic reticulum and mitochondria, modulates the unfolded protein response, and activates anti-inflammatory and antiapoptotic signaling cascades [3, 4]. Activation of sigma-1R by AF710B has been linked to rescue of mushroom spine loss in presenilin-1 knock-in and APP knock-in neuronal cultures, reduction of neuroinflammatory markers, and normalization of brain-derived neurotrophic factor (BDNF) signaling in transgenic models [1, 5]. In the seminal Fisher et al. (2016) study, AF710B administered to female 3xTg-AD mice at 10 micrograms per kilogram intraperitoneally daily for two months mitigated cognitive impairment in the Morris water maze and reduced BACE1 expression, GSK3-beta activity, p25/CDK5 levels, neuroinflammation, soluble and insoluble amyloid-beta 40 and 42, amyloid plaques, and phosphorylated tau pathology [1]. A subsequent study by Hall et al. (2018) in Alzheimer’s and Dementia extended these findings to the McGill-R-Thy1-APP transgenic rat model, demonstrating that chronic oral AF710B at 10 micrograms per kilogram daily for 4.5 months in 13-month-old (post-plaque) rats reversed cognitive deficits, reduced hippocampal amyloid plaque burden and cortical amyloid-beta 40 and 42 levels, decreased neuroinflammatory markers, increased cerebrospinal fluid amyloid clearance, and elevated the synaptic marker synaptophysin [6]. The disease-modifying character of the effect was underscored by its persistence through a five-week drug washout period following treatment cessation. A third study (Bhatt et al., 2024, Neurobiology of Aging) confirmed that early treatment with AF710B in the same rat model prevented cognitive decline when treatment was initiated before overt plaque deposition [7]. Anavex Life Sciences Corporation acquired exclusive worldwide rights to the AF710B intellectual property in 2014 and advanced the compound under the designation ANAVEX 3-71 through a first-in-human Phase 1 single ascending dose study in 42 healthy volunteers (2020 to 2021), which demonstrated safety and tolerability at oral doses of 5 to 200 mg with no serious adverse events, no clinically significant electrocardiogram changes, and linear, dose-proportional pharmacokinetics with a mean terminal elimination half-life of approximately 3.56 hours [8, 9]. A Phase 1b study subsequently confirmed the bioavailability of a once-daily oral tablet formulation. In 2024, Anavex initiated a placebo-controlled Phase 2 study (ANAVEX3-71-SZ-001) in adults with schizophrenia, and in October 2025 reported positive topline results demonstrating safety, tolerability, reduction in the neuroinflammatory biomarker glial fibrillary acidic protein (GFAP), and encouraging trends in EEG and event-related potential biomarkers [10, 11]. The compound has received orphan drug designation from the FDA for frontotemporal dementia. No registration-enabling Phase 3 trial has been completed for any indication as of the most recent monograph revision. This monograph documents the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing and handling considerations, stack interactions, adverse-event profile, and a structured comparative assessment of AF710B against five muscarinic and sigma-1 receptor candidates on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1456Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
17-DMAG

Our opinion on this compoundNiche research probe

50/100

Clinically-halted HSP90 inhibitor with real bench utility and a credible neuroprotective second act

Look, 17-DMAG is one of those compounds that reads well on paper and disappoints at the clinic. Alvespimycin is a second-generation benzoquinone ansamycin HSP90 inhibitor, developed at NCI and Kosan Biosciences to fix the pharmacokinetic liabilities of tanespimycin (17-AAG), and it largely achieved what it set out to do chemically. The dimethylaminoethylamino substitution at C-17 delivers real improvements: better aqueous solubility, lower plasma protein binding, oral bioavailability, and a cleaner metabolic profile than its parent. On paper, thats a meaningful upgrade from a first-generation compound with serious formulation problems.

The mechanism is genuinely interesting. HSP90 chaperoning is deeply embedded cellular machinery, and hitting the N-terminal ATP pocket doesn’t just block one target. It deploys clients including HER2, AKT, RAF-1, BCR-ABL, FLT3, and mutant p53 to ubiquitin-proteasome degradation in a single pharmacological move. That multi-client degradation logic was ahead of its time in the early 2000s and remains one of the more compelling polypharmacological approaches in the cancer biology toolkit. Preferential accumulation in tumor tissue via the high-affinity multi-chaperone HSP90 complex conformation found in malignant cells adds genuine selectivity rationale, not just hand-waving.

What we don’t like: clinical development was halted in 2008. Kosan ran four Phase I trials covering weekly IV in solid tumors, twice-weekly IV in advanced malignancies, AML combinations with cytarabine, and trastuzumab combinations in HER2-positive disease. The MTD in the weekly IV study was 80 mg/m2, with dose-limiting hepatotoxicity and ocular toxicity, including keratitis and blurred vision, at 106 mg/m2 including one treatment-related death. There was clinical activity: complete responses in AML, signals in refractory HER2-positive breast cancer. But the therapeutic window stayed too narrow and the CLL/SLL trial showed tolerability without objective responses. Kosan couldn’t build a Phase II case, and that decision has stood since.

The research landscape has also moved past the ansamycin series on most fronts. Ganetespib and luminespib were designed specifically to shed the benzoquinone toxicity scaffold while retaining N-terminal binding. Pimitespib (TAS-116) completed Phase III registration in Japan. Within its own geldanamycin subclass, 17-DMAG outperforms tanespimycin on PK and solubility, but thats a narrow win in a class that has largely been displaced for clinical development purposes.

There is a legitimate second life here, and its worth taking seriously. Post-clinical work in rodent stroke and intracerebral hemorrhage models characterizes 17-DMAG as neuroprotective through NF-κB suppression, blood-brain barrier preservation, and PI3K/Akt modulation via SOX5 targeting. Those are real signals in systems where HSP90 biology intersects with neuroinflammation in ways the field is still working out. As a bench tool for studying HSP90 client dynamics, HSF1 activation patterns, or chaperone-driven neuroinflammation crosstalk, it’s genuinely useful, and the water-solubility advantage over geldanamycin makes it actually workable in aqueous in vivo systems. We think thats where 17-DMAG belongs right now: a legitimate probe compound for investigators working the HSP90-neuroinflammation axis, not a primary development candidate.

Novelty

40

Mechanism promise

65

In-category differentiation

40

Evidence quality

55

Translational signal

40

Research bench value

65

Rationale Mechanism scores well due to HSP90’s elegant multi-client degradation approach and the NF-κB neuroinflammation angle, but clinical development halt in 2008, narrow therapeutic window, and displacement by non-ansamycin HSP90 inhibitors suppress differentiation and translational scores to produce a mid-range niche-probe result.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Semi-synthetic benzoquinone ansamycin and heat shock protein 90 (HSP90) N-terminal ATPase inhibitor derived from geldanamycin

A water-soluble geldanamycin derivative developed as a second-generation HSP90 inhibitor with improved pharmacokinetic properties relative to tanespimycin, advanced through Phase I oncology trials and subsequently investigated for neuroprotective and anti-inflammatory applications.

Abstract

17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin; alvespimycin; KOS-1022; NSC 707545) is a semi-synthetic derivative of the benzoquinone ansamycin natural product geldanamycin that binds the N-terminal adenosine triphosphate (ATP) binding pocket of heat shock protein 90 (HSP90) with an IC50 of approximately 24 nanomolar. The compound was developed at the National Cancer Institute (NCI) and by Kosan Biosciences as a water-soluble, orally bioavailable successor to the first-in-class HSP90 inhibitor tanespimycin (17-AAG), from which it is distinguished by the replacement of the C-17 allylamino substituent with a dimethylaminoethylamino group. This substitution confers substantially improved aqueous solubility, reduced hepatic metabolic liability, lower plasma protein binding, and higher oral bioavailability while maintaining or exceeding the antitumor potency of the parent compound in preclinical models. HSP90 is a molecular chaperone essential for the conformational maturation and stabilization of numerous client proteins involved in oncogenic signaling, including HER2/ErbB2, AKT, RAF-1, mutant p53, BCR-ABL, FLT3, KIT, and the inhibitor of nuclear factor kappa-B kinase (IKK) subunits. Binding of 17-DMAG to the HSP90 N-terminal domain displaces the chaperone from its client proteins, targeting them for ubiquitin-proteasome-mediated degradation and simultaneously inducing compensatory heat shock factor 1 (HSF1) activation and upregulation of HSP70 and HSP27 as pharmacodynamic biomarkers of target engagement. The compound preferentially accumulates in tumor tissue relative to normal tissue owing to the higher-affinity, multi-chaperone HSP90 complex conformation present in malignant cells, resulting in a degree of tumor selectivity that is pharmacologically meaningful despite the ubiquitous expression of HSP90 in normal physiology. In preclinical evaluation, 17-DMAG demonstrated broad-spectrum antitumor activity across the NCI 60-cell-line panel (mean GI50 approximately 53 nanomolar) and in xenograft models of melanoma, non-small cell lung cancer, pancreatic cancer, and pediatric solid tumors, with oral and parenteral routes both producing tumor growth inhibition and client protein degradation at tolerated doses. Pharmacokinetic studies in CD2F1 mice and Fischer 344 rats demonstrated wide tissue distribution, linear pharmacokinetics, predominantly hepatobiliary elimination, and quantitatively less extensive metabolism than tanespimycin. Clinical development encompassed four Phase I trials: a weekly intravenous schedule in advanced solid tumors (maximum tolerated dose 80 mg/m2, with dose-limiting hepatic and ocular toxicity at 106 mg/m2 including one treatment-related death); a twice-weekly intravenous schedule in advanced malignancies (recommended Phase 2 dose 24 mg/m2); a twice-weekly schedule in acute myeloid leukemia (AML) demonstrating target inhibition and signs of clinical activity including complete responses in combination with chemotherapy; and a weekly combination with trastuzumab in HER2-positive advanced solid tumors (recommended dose 80 mg/m2 weekly with trastuzumab, with antitumor activity in refractory HER2-positive metastatic breast cancer). A separate Phase I trial in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) demonstrated tolerability without objective responses at the doses studied. Common clinical adverse events included nausea, vomiting, fatigue, hepatic transaminase elevation, and ocular toxicity (blurred vision, dry eye, keratitis). In March 2008, Kosan Biosciences halted clinical development of alvespimycin on the basis of an unfavorable overall toxicity profile relative to the therapeutic window, and the compound has not been advanced to Phase II or Phase III registration trials as a single agent. Subsequent non-oncologic research has characterized 17-DMAG as a neuroprotective agent in rodent models of ischemic stroke and intracerebral hemorrhage, operating through suppression of NF-kappaB-mediated neuroinflammation, reduction of blood-brain barrier disruption, and modulation of the PI3K/Akt signaling pathway via SOX5 targeting. This monograph reviews the chemistry, synthesis, and structural pharmacology of 17-DMAG; the HSP90 chaperone biology and client protein degradation mechanism; the preclinical pharmacology across oncologic and neurologic models; the comprehensive human pharmacokinetic record; the clinical evidence base across all studied indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five HSP90 inhibitor candidates against 17-DMAG on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1477Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
SkQ1

Plain-language summaryIntrigue 67 / 100

SkQ1 (Visomitin) is the Russian answer to MitoQ: a mitochondria-targeted antioxidant that uses a positively charged triphenylphosphonium tail to drag plastoquinone, an antioxidant from plant chloroplasts, deep into the mitochondrial inner membrane where oxidative damage actually happens. The molecule was developed by Vladimir Skulachev, one of the giants of mitochondrial bioenergetics, and his group has produced extensive preclinical data in aging models. It is approved as eye drops in Russia for dry eye disease, with measurable clinical benefit. The lifespan and longevity data come almost entirely from Skulachev’s lab, which is the principal weakness of the file. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Elegant rechargeable mitochondrial antioxidant; broad single-lab preclinical, Phase 3 failures in primary indication

Look, the mechanism here is genuinely clever. The triphenylphosphonium cation exploits the roughly 180-millivolt mitochondrial membrane potential to drive electrophoretic accumulation estimated at 10^8-fold above extracellular concentrations – thats a real selectivity story, not a rounding error. What sets SkQ1 apart from MitoQ is the plastoquinone headgroup rather than ubiquinone: it intercalates near cardiolipin fatty acid chains, and the rechargeable cycle regenerated by Complex I at the IQ site and Complex III at the Qi site means this isnt a stoichiometric scavenger burning itself out. Nanomolar external concentrations, sustained catalytic activity. That’s elegant chemistry and we credit it heavily on mechanism.

The Skulachev group at Moscow State built an unusually broad preclinical portfolio: lifespan extension across fungi, crustaceans, Drosophila, killifish, and multiple rodent strains; prevention and reversal of cataracts, retinopathy, osteoporosis, and Alzheimer-like pathology in the OXYS rat; cardio-, nephro-, and neuroprotection across acute injury models; ferroptosis suppression in cisplatin and ischemia-reperfusion kidney models. The breadth is real and mechanistic consistency across model systems is genuinely encouraging. Here’s the thing, though: almost all of this traces back to a single research consortium. Skulachev’s lab defines the literature in a way thats uncomfortably close to what we say about BPC-157 or Epitalon. Independent replication outside the Russian program is sparse, and for a compound making longevity claims across six phyla, that’s a hard credibility ceiling.

The clinical picture is mixed in a way that matters. Visomitin got Russian Ministry of Health approval in 2011 for dry eye syndrome, and the US Phase 2 trial in 91 subjects showed statistically significant improvement in corneal fluorescein and lissamine green staining – a genuine positive signal. Then VISTA-1 and VISTA-2 happened: 452 and 610 subjects respectively, primary co-endpoints missed in both. VISTA-2 showed significance on a pre-specified secondary endpoint in a Schirmer’s-defined subpopulation, which is exactly the kind of result that keeps a compound alive in funding conversations but doesnt move the scientific needle much. Phase 3 failures in the primary indication are evidence-quality limiters, full stop.

Where SkQ1 retains real value is as a bench probe. For research programs interrogating mitochondrial ROS contributions to age-related pathology, ferroptosis mechanisms, ischemia-reperfusion injury, or mtROS-driven inflammation, SkQ1 is a chemically well-characterized, concentration-dependent tool with a documented safety window and no CYP450 induction liability. The rechargeable mechanism is a genuine feature in chronic-exposure experimental designs. It belongs in a serious mitochondria-research toolkit alongside SS-31 and MitoQ, though it doesnt clearly dominate either. The 51 reflects a compound with an interesting mechanism and genuine preclinical breadth that hasn’t cleared the clinical bar, backed by literature that needs substantially more independent replication before earning a higher ranking.

Novelty

48

Mechanism promise

72

In-category differentiation

45

Evidence quality

40

Translational signal

38

Research bench value

60

Rationale The rechargeable TPP-driven mitochondrial accumulation mechanism scores well on mechanism promise, and the preclinical breadth across six phyla is genuine, but the evidence base is heavily Skulachev-consortium-dominated and Phase 3 ophthalmology failures (VISTA-1/VISTA-2) meaningfully constrain both evidence quality and translational signal; bench utility for mtROS research is solid but not indispensable.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mitochondria-targeted plastoquinone-based antioxidant conjugated to a penetrating lipophilic cation (triphenylphosphonium)

A rechargeable, mitochondria-accumulating plastoquinone derivative developed at Lomonosov Moscow State University as a direct scavenger of reactive oxygen species at the inner mitochondrial membrane, with preclinical geroprotective, cytoprotective, and anti-inflammatory activity across multiple organ systems and a registered ophthalmic formulation (Visomitin) for dry eye syndrome.

Abstract

SkQ1 (10-(6′-plastoquinonyl)decyltriphenylphosphonium), designated a “Skulachev ion” after its principal developer Vladimir P. Skulachev, is a synthetic mitochondria-targeted antioxidant composed of a plastoquinone moiety linked by a ten-carbon aliphatic chain to a triphenylphosphonium cation. The triphenylphosphonium group exploits the large negative-inside mitochondrial membrane potential (approximately 180 millivolts) to drive electrophoretic accumulation of the compound within the mitochondrial matrix at concentrations estimated to reach 10(8)-fold above extracellular levels. Within the inner mitochondrial membrane, the plastoquinone headgroup intercalates near the cardiolipin fatty acid chains and directly quenches peroxyl radicals, with regeneration of the reduced (antioxidant-active) form by Complex I at the IQ site and by Complex III at the Qi site of the electron transport chain. This rechargeable antioxidant cycle distinguishes SkQ1 from stoichiometric scavengers and positions it as a catalytic antioxidant with sustained activity at nanomolar external concentrations. The compound was developed beginning in the early 2000s at the A. N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, within a research framework centered on Skulachev’s hypothesis that aging represents a form of programmed organismal death (phenoptosis) mediated by mitochondrial reactive oxygen species (mtROS). Preclinical studies in organisms spanning fungi (Podospora anserina), crustaceans (Ceriodaphnia affinis), insects (Drosophila melanogaster), fish (Nothobranchius furzeri), and mammals (mice and rats) have demonstrated lifespan extension, delay or reversal of age-related pathologies, and suppression of mtROS-driven tissue damage under a variety of experimental conditions. In the senescence-accelerated OXYS rat strain, SkQ1 prevented or reversed cataracts, retinopathy resembling age-related macular degeneration, osteoporosis, and neurodegenerative phenotypes resembling Alzheimer’s disease. In outbred and inbred mouse strains, SkQ1 extended median and maximum lifespan under non-specific-pathogen-free housing conditions, with effect sizes dependent on ambient pathogen exposure. The compound prevented rapid death caused by mechanistically diverse acute shocks including bacterial lipopolysaccharide, intravenous mitochondrial injection, cold exposure, and toxic insult. The ophthalmic formulation of SkQ1 (Visomitin, 0.155 micrograms per milliliter ophthalmic solution) was approved by the Russian Ministry of Health in December 2011 for the treatment of dry eye syndrome and early cataracts. In the United States, Mitotech S.A. advanced SkQ1 ophthalmic solution through a positive Phase 2 clinical trial demonstrating statistically significant improvement in corneal fluorescein staining and lissamine green staining relative to placebo in 91 subjects with mild to moderate dry eye disease. Two subsequent Phase 3 studies (VISTA-1, 452 subjects; VISTA-2, 610 subjects) did not meet their co-primary endpoints, although VISTA-2 demonstrated statistically significant superiority in a pre-specified secondary endpoint of central corneal fluorescein staining change in a Schirmer’s score-defined subpopulation. Phase 1 oral formulation studies were conducted in Russia in 2016. Preclinical pharmacology extends beyond ophthalmology to include cardioprotection (hemorrhagic shock, doxorubicin-induced cardiomyopathy), nephroprotection (cisplatin-induced and ischemia-reperfusion acute kidney injury with ferroptosis inhibition), neuroprotection (stroke, Alzheimer’s disease models in OXYS rats), hepatoprotection, suppression of experimental colitis and autoimmune arthritis, wound healing acceleration, tumor growth inhibition in fibrosarcoma and rhabdomyosarcoma models, and antibacterial activity at micromolar concentrations. Safety pharmacology in rats and dogs has demonstrated a wide therapeutic window with no adverse effects on the central nervous system, cardiovascular system, or respiratory system at doses orders of magnitude above the efficacious range. The compound does not induce hepatic cytochrome P450 enzymes. This monograph reviews the chemistry, structural pharmacology, and rechargeable antioxidant mechanism of SkQ1; the comprehensive preclinical evidence across geroprotective, cytoprotective, and anti-inflammatory applications; the clinical evidence base in dry eye disease; the pharmacokinetic characteristics; sourcing and quality considerations; reconstitution and handling protocols; stack-interaction implications; the adverse-event and safety profile; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates against SkQ1 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1467Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026
Xanomeline-Trospium

Our opinion on this compoundNovel frontier

77/100

First non-dopaminergic antipsychotic mechanism approved in 70 years, genuinely novel M1/M4 agonism approach

Look, xanomeline-trospium is genuinely hard to overstate from a mechanistic standpoint. Schizophrenia pharmacology has been stuck in the dopamine D2 antagonism paradigm since chlorpromazine was discovered accidentally in the 1950s. Every antipsychotic approved in the intervening seven decades works primarily through D2 blockade. Xanomeline-trospium does not. Its FDA approval in September 2024 marks the first registered antipsychotic with a wholly distinct mechanism since the field started. That’s not marketing language; thats a clinical pharmacology fact.

The xanomeline story starts in 1993 at Eli Lilly, where it entered development as a potential Alzheimer’s treatment. The central M1/M4 agonism produced real cognitive and behavioral effects in early clinical trials, but dose-limiting peripheral cholinergic side effects killed the program. The insight that eventually got it over the finish line came from pairing it with trospium chloride, a quaternary ammonium compound that blocks peripheral muscarinic receptors without crossing the blood-brain barrier. Elegant, honestly. You get the central pharmacology, and the gut stays quiet.

Why does M1/M4 agonism work in schizophrenia? The hypothesis is that muscarinic cholinergic hypofunction contributes meaningfully to positive symptoms, negative symptoms, and cognitive deficits through modulation of dopaminergic and glutamatergic circuits. M4 receptors are heavily expressed in the striatum and regulate dopamine release indirectly. M1 is critical for prefrontal cortical function and working memory. The EMERGENT program tested this rigorously. EMERGENT-1 (phase 2, n=182) showed statistically significant PANSS reductions. EMERGENT-2 and EMERGENT-3 were phase 3 confirmatory trials that both replicated the signal with meaningful effect sizes, and without the EPS, metabolic disruption, or prolactin elevation that characterize D2-class agents.

What we find particularly compelling for research purposes is the safety divergence. No meaningful extrapyramidal symptoms. No clinically significant metabolic shift. Prolactin stays flat. For investigators modeling treatment-resistant schizophrenia or studying cognitive deficits in psychotic illness, this compound opens experimental doors that D2 antagonists actively close, because D2 blockade confounds dopamine circuitry in ways that are hard to separate from disease effects. Xanomeline-trospium lets you probe cholinergic contributions to psychosis without that noise.

The evidence base is solid for a newly approved agent: three completed trials, FDA registration, and long-term extension data accumulating. The pipeline is also active for Alzheimer’s disease, where the original xanomeline signal is being revisited with the combination. We think the translational story here is among the strongest in CNS drug development right now. The main honest caveat is that post-marketing experience is still thin, and the long-term safety picture will sharpen over the next few years. But as a research tool and as a category-defining approved agent, this one warrants serious attention.

Novelty

72

Mechanism promise

83

In-category differentiation

82

Evidence quality

75

Translational signal

75

Research bench value

68

Rationale Scores high on novelty and mechanism because it’s the first approved non-D2 antipsychotic in history, with the combination strategy representing a genuine pharmacological advance; three EMERGENT trials provide a solid evidence base, differentiation is strong with no approved competitor in its class, though evidence maturity is still early at just over one year post-approval.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Fixed-dose combination of an M1/M4-preferring muscarinic acetylcholine receptor agonist and a peripherally restricted non-selective muscarinic antagonist

A first-in-class muscarinic agonist combination pairing the centrally acting M1/M4-preferring agonist xanomeline with the peripherally restricted muscarinic antagonist trospium chloride, approved by the United States Food and Drug Administration in September 2024 for the treatment of schizophrenia in adults, representing the first non-dopamine-D2-blocking antipsychotic mechanism registered for psychotic illness.

Abstract

Xanomeline-trospium (KarXT; marketed as Cobenfy) is a fixed-dose oral combination of xanomeline tartrate, a functionally selective muscarinic acetylcholine receptor agonist with preferential activity at the M1 and M4 receptor subtypes, and trospium chloride, a quaternary ammonium muscarinic antagonist that does not appreciably cross the blood-brain barrier. The combination was designed to preserve the central antipsychotic and procognitive effects of muscarinic M1/M4 agonism while mitigating the dose-limiting peripheral cholinergic adverse events (nausea, vomiting, diarrhea, hypersalivation, diaphoresis) that had previously terminated the clinical development of xanomeline as a monotherapy agent. The United States Food and Drug Administration approved xanomeline-trospium on 26 September 2024 for the treatment of schizophrenia in adults, making it the first antipsychotic mechanism approved since the introduction of the dopamine D2 receptor antagonist and partial agonist classes and the first muscarinic-based treatment registered for any psychotic disorder.

Xanomeline was originally synthesized in a collaboration between Eli Lilly and Novo Nordisk in the early 1990s under the development code LY-246708. Initial clinical development targeted Alzheimer’s disease, where a 343-patient Phase 2 trial (Bodick et al. 1997) demonstrated stabilization of cognitive decline and significant dose-dependent reductions in behavioral and psychological symptoms including hallucinations, delusions, agitation, and vocal outbursts. However, peripheral cholinergic adverse events led to unacceptable dropout rates and the Alzheimer’s program was discontinued. A subsequent proof-of-concept trial in schizophrenia (Shekhar et al. 2008) confirmed antipsychotic-like activity through a non-dopaminergic mechanism but was similarly limited by tolerability. The critical innovation was the combination with trospium chloride, a muscarinic antagonist previously approved for overactive bladder (Sanctura, Allergan) that is restricted to the peripheral compartment by its quaternary ammonium structure and does not undergo cytochrome P450 metabolism. This combination strategy was advanced by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb for approximately 14 billion United States dollars in 2024.

The registration of xanomeline-trospium was supported by three randomized, double-blind, placebo-controlled, 5-week Phase 3 trials (EMERGENT-1, EMERGENT-2, EMERGENT-3) in adults with schizophrenia experiencing acute psychosis. In pooled analyses across all three trials, xanomeline-trospium produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (least squares mean difference, minus 9.9 points; 95 percent confidence interval, minus 12.4 to minus 7.3; p less than 0.0001; Cohen’s d effect size, 0.65). Effects were observed across positive symptom, negative symptom, and general psychopathology PANSS subscales and on the Clinical Global Impression-Severity scale. Long-term safety and efficacy were characterized in the 52-week open-label extension trials EMERGENT-4 and EMERGENT-5, which demonstrated sustained symptom improvement, a mean change in body weight of minus 1.9 kilograms from acute trial baseline, no clinically meaningful changes in prolactin levels, and no treatment-emergent akathisia or tardive dyskinesia. The most common adverse events were gastrointestinal (nausea, dyspepsia, constipation, vomiting) and were generally mild to moderate, transient, and manageable without treatment discontinuation in most patients.

The compound is currently in Phase 3 development for additional indications including psychosis associated with Alzheimer’s disease (ADEPT program), agitation associated with Alzheimer’s disease (ADAGIO program), and cognitive impairment in Alzheimer’s disease. An enteric-coated xanomeline formulation (KarX-EC) is in development with the aim of further reducing gastrointestinal adverse events. This monograph reviews the chemistry, synthesis, and pharmacology of both components; the composite mechanism of action through central muscarinic M1/M4 agonism with peripheral muscarinic blockade; the pharmacokinetics including CYP2D6 polymorphism effects; the complete clinical evidence base across schizophrenia and Alzheimer’s disease indications; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five alternative antipsychotic or muscarinic-targeted agents against xanomeline-trospium on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1457Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 13, 2026

←Previous Page

1 … 20 21 22 23 24 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.